To meet growing industry needs for AAV, we have developed the VirusExpress® 293 AAV production platform and established an upstream process for AAV manufacturing. It utilizes a suspension-adapted cell line in chemically defined media using plasmid based, transient transfection. We have advanced the platform by utilizing a high-throughput automated microbioreactor system and a DOE approach. Improvements have been made to the transfection process and cell culture media. Join our webinar to learn how to speed through AAV manufacturing.
In this webinar, you will learn:
- How our VirusExpress® 293 AAV Production Platform can help speed your gene therapy for patients
- How high-throughput screening has enhanced the efficiency of the platform
- How improvements to transfection and cell culture media impact performance
- How our platform performs with GFP model virus in serotypes AAV2, AAV5, AAV6, and other application data
Speakers
Henry George
Merck
Head of R&D for Viral Vector Producer Cell Lines
Since 1981, Henry has worked in both the biotechnology and pharmaceutical sectors, developing protein expression systems in bacterial, insect, and mammalian hosts. He joined our company in 2001 as an R&D manager, and currently leads a viral vector producer cell lines R&D group.
Andi Ushijima
Merck
Scientist, Viral Vector Technology and Innovation
Andi Ushijima is a scientist in the viral vector innovation and technology group at Merck. She has a lot of experience with upstream bioprocessing, working on bioreactor development and scale-up of monoclonal antibodies, virus-like particles, and viral vectors. She received her B.S. in bioengineering at UCSD.
Pharma and biopharma manufacturing
- Viral Vector Upstream Processing
期間:1h
言語:English
セッション 1:presented October 6, 2022
続きを確認するには、ログインするか、新規登録が必要です。
アカウントをお持ちではありませんか？